BR112014030039A2 - heterociclos bicíclicos capazes de modular respostas de células t e métodos de uso dos mesmos - Google Patents

heterociclos bicíclicos capazes de modular respostas de células t e métodos de uso dos mesmos

Info

Publication number
BR112014030039A2
BR112014030039A2 BR112014030039A BR112014030039A BR112014030039A2 BR 112014030039 A2 BR112014030039 A2 BR 112014030039A2 BR 112014030039 A BR112014030039 A BR 112014030039A BR 112014030039 A BR112014030039 A BR 112014030039A BR 112014030039 A2 BR112014030039 A2 BR 112014030039A2
Authority
BR
Brazil
Prior art keywords
cell responses
bicyclic heterocycles
methods
modulating
disorders
Prior art date
Application number
BR112014030039A
Other languages
English (en)
Portuguese (pt)
Inventor
Verhaar Auke
Hommes Daan
Viti Francesca
Van Den Brink Gijs
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of BR112014030039A2 publication Critical patent/BR112014030039A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112014030039A 2012-06-01 2013-05-31 heterociclos bicíclicos capazes de modular respostas de células t e métodos de uso dos mesmos BR112014030039A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261654398P 2012-06-01 2012-06-01
PCT/EP2013/061328 WO2013178815A1 (en) 2012-06-01 2013-05-31 Bicyclic heterocycles capable of modulating t-cell responses, and methods of using same

Publications (1)

Publication Number Publication Date
BR112014030039A2 true BR112014030039A2 (pt) 2017-06-27

Family

ID=48538005

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014030039A BR112014030039A2 (pt) 2012-06-01 2013-05-31 heterociclos bicíclicos capazes de modular respostas de células t e métodos de uso dos mesmos

Country Status (11)

Country Link
US (2) US20150126553A1 (https=)
EP (1) EP2861563B1 (https=)
JP (1) JP2015521195A (https=)
KR (1) KR20150016377A (https=)
CN (1) CN104619687A (https=)
AU (1) AU2013269550A1 (https=)
BR (1) BR112014030039A2 (https=)
CA (1) CA2874919A1 (https=)
IN (1) IN2014DN10214A (https=)
MX (1) MX2014014657A (https=)
WO (1) WO2013178815A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
WO2010091894A2 (en) 2009-02-16 2010-08-19 Giuliani International Limited Methods of treating hair related conditions
CN109999017A (zh) 2012-02-09 2019-07-12 诺格拉制药有限公司 治疗纤维化的方法
CN104284655B (zh) 2012-04-18 2017-10-27 诺格拉制药有限公司 治疗乳糖不耐受的方法
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
CA3010615C (en) 2016-01-14 2024-02-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
MX2020010155A (es) * 2018-03-27 2021-03-25 Univ Texas Compuestos de ox2r.
EP4495101A3 (en) 2019-02-08 2025-04-30 Nogra Pharma Limited Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
CR20220565A (es) 2020-05-06 2023-01-13 Merck Sharp & Dohme Llc Inhibidores de il4i1 y métodos de uso

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1069385A1 (ru) * 1982-05-07 1990-11-15 Научно-исследовательский институт фармакологии АМН СССР Бромид 2-амино-3-(1-адамантилкарбонилметил)-1-( @ -пиперидино-этил)-бензимидазоли , обладающий способностью угнетать иммунитет
US7868028B2 (en) * 2002-06-17 2011-01-11 Fred Drasner Guanidine compounds as anesthetics and for treatment of nervous system disorders
CA2601458C (en) * 2005-03-15 2011-04-26 Pfizer Inc. Benzimidazolone derivatives as cb2 receptor ligands
EP1926734A1 (en) * 2005-08-22 2008-06-04 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
WO2007084728A2 (en) * 2006-01-19 2007-07-26 Abbott Laboratories 2-imino-benzimidazoles
US20080206287A1 (en) * 2006-09-18 2008-08-28 Reed John C Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands
HRP20191953T8 (hr) * 2008-03-07 2021-06-25 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. DERIVATI 1-BENZIL-3-HIDROKSIMETILINDAZOLA I NJIHOVA UPORABA U LIJEČENJU BOLESTI KOJE SE BAZIRAJU NA EKSPRESIJI MCP-1, CX3CR1 i P40
EP2262777B8 (en) * 2008-03-07 2016-05-04 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1 and cx3cr1

Also Published As

Publication number Publication date
AU2013269550A1 (en) 2014-12-18
US20170183313A1 (en) 2017-06-29
KR20150016377A (ko) 2015-02-11
JP2015521195A (ja) 2015-07-27
WO2013178815A1 (en) 2013-12-05
MX2014014657A (es) 2015-08-10
US20150126553A1 (en) 2015-05-07
IN2014DN10214A (https=) 2015-08-07
EP2861563A1 (en) 2015-04-22
EP2861563B1 (en) 2017-07-12
CA2874919A1 (en) 2013-12-05
CN104619687A (zh) 2015-05-13

Similar Documents

Publication Publication Date Title
BR112014030039A2 (pt) heterociclos bicíclicos capazes de modular respostas de células t e métodos de uso dos mesmos
BR112014030050A2 (pt) heterociclos capazes de modular as respostas das células t, e métodos de utilizar os mesmos
BR112015023760A2 (pt) compostos e composições terapêuticas
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
EA201590881A1 (ru) Терапевтические соединения и композиции и их использование в качестве модуляторов пк-m2
EA201590999A1 (ru) Пирролобензодиазепины и их конъюгаты
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
EA201300730A1 (ru) Производные индазолилтриазола
BR112014016805A2 (pt) compostos terapeuticamente ativos e seus métodos de uso
MX380943B (es) Compuestos terapeuticamente activos y sus metodos de uso.
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
PH12012502138B1 (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
CY1117565T1 (el) Συνενωμενο δικυκλικο παραγωγο 2,4-διαμινοπυριδινης ως διπλος αναστολεας alk και fak
MX381260B (es) Inhibidores heterociclicos de glutaminasa.
BR112015032902A8 (pt) compostos de heteroarila, seus usos e composições farmacêuticas
BR112014019990A8 (pt) Compostos enediinos, seus conjugados e usos e métodos para esses compostos
BR112017002214A2 (pt) composto de fórmula (i), composição farmacêutica e usos de um composto
BR112012024822B8 (pt) Composto, uso de um composto e composição farmacêutica
EA201491747A1 (ru) Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов
MX370900B (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
NZ629914A (en) New derivatives of 5-aminolevulinic acid and their use as photosensitizing agents
BR112016016130A2 (pt) Compostos e métodos
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06I Technical and formal requirements: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A ANUIDADE.

B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2517 DE 02-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.